Skip to main content
Premium Trial:

Request an Annual Quote

Richard Bender, Mark Day, Tara Hennen

Premium
Agendia has named Richard Bender as VP and chief medical officer.
 
Bender was medical director in the oncology division of Quest Diagnostics, and he was involved in clinical oncology at Kaiser Permanente. Bender also was on the executive board of San Diego’s Hospice and the American Cancer Society and he was an instructor at the UCLA School of Medicine.
 

 
PsychoGenics has named Mark Day to be senior director of cognitive neuroscience. Day formerly was involved in developing cognitive treatments for schizophrenia and Alzheimer’s disease at Wyeth Neuroscience and at GlaxoSmithKline.
 

 
Pacific Biomarkers has named Tara Hennen, a member of the company’s science and technology group, to be manager of its Biomarker Lab Services business.

Filed under

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.